TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01882231

Intervention type: OTHER
Group type: OTHER
Intervention: DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI
Description: Imaging techniques using high-field MRI to make quantitative assessments in patients with osteosarcoma or Ewing sarcoma
Study: NCT02131337

Intervention type: OTHER
Group type: OTHER
Intervention: Electrophysiology study
Description: after 3 months to check for pulmonary vein isolation (PVI) status
Study: NCT02746705

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS is a therapeutic development that utilizes low amplitude direct currents to induce changes in cortical excitability. tDCS is expected to produce neuronal polarization of less than one mV (millivolt) 9. tDCS produces relatively diffuse current flow, as demonstrated by imaging studies and computational models

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: During a sham session, the device is programmed to ramp up to the desired intensity (target 2.0 mA) and ramp down for the initial 60 seconds, with no current delivery during the session, and then again at the end of the session. These brief periods of stimulation serve to mimic the effects of a true stimulation session.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Training Program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training Program
Study: NCT02701816

Intervention type: DEVICE
Intervention: innova stent (Boston scientific)
Study: NCT00665197

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Protracted Course Radiotherapy
Description: External Beam Radiation 30 Gy in 10 fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short Course Radiotherapy
Description: External Beam Radiation 20 Gy in 5 fractions
Study: NCT04067024

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia made by surgeon
Description: infiltration with local anesthetics

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional anesthesia group
Description: Pecs block I and Supraclavicular nerf block
Study: NCT01406275

Intervention type: DRUG
Intervention: Amoxicillin and clavulanate
Study: NCT03147001

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein ingestion
Description: A protein drink was ingested prior to the 90min bike ride in one of the completed trails (order randomised).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-caloric placebo ingestion
Description: A placebo drink was ingested prior to the 90min bike ride in one of the completed trails (order randomised).
Study: NCT00732771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCI699
Study: NCT01872468

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured intervention
Description: Initial training session based on patient personal experiences and reflexion (30 minutes). CKD learning session (30 minutes). Personal plan of actions to cope with own disease (30 minutes. Discussion of doubts (30 minutes). Follow up visits every four months at physicians and nurses´ offices over a two-year period
Study: NCT00971399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramosetron
Description: ramosetron 0.1mg q.d. SL on D1-5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: ondansetron 8mg, b.i.d SL on D1-5
Study: NCT00908531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole (Femara)
Description: tablet 2.5 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole (Femara)
Description: tablet 2.5 mg daily
Study: NCT01001663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FemoSeal®
Description: Closure device for femoral artery access closure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual compression
Description: Conventional manual compression
Study: NCT01559961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-1612
Description: Single intravesical 30-minute treatments with escalating doses of TTI-1612.
Study: NCT01989650

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Break
Description: A break of 15 minute will be provided after 3rd colonoscopy in a session of 6 colonoscopies in total

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No break
Description: No break will be provided
Study: NCT00511004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Comparing 400 mg to 800 mg dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Comparing 400 mg to 800 mg dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Comparing 400 mg to 800 mg dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diethylcarbamazine
Description: Providing diethylcarbamazine more frequently in combination with albendazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diethylcarbamazine
Description: Providing diethylcarbamazine more frequently in combination with albendazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diethylcarbamazine
Description: Providing diethylcarbamazine more frequently in combination with albendazole
Study: NCT01242475

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-Tb
Description: The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 TU Tuberculin PPD RT 23 SSI
Description: The 2TU Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
Study: NCT00775749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transdermal nicotine patch
Description: The 7 mg transdermal nicotine patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch
Description: The placebo patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
Study: NCT02078284

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPP
Description: One unit of frozen CPP contains approximately 3.4 x 10\^11 irradiated platelets and approximately 6% DMSO in sterile 0.9% sodium chloride solution (total volume of 20 mL to 35 mL) stored frozen at ≤ -65°C.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPP
Description: One unit of frozen CPP contains approximately 3.4 x 10\^11 irradiated platelets and approximately 6% DMSO in sterile 0.9% sodium chloride solution (total volume of 20 mL to 35 mL) stored frozen at ≤ -65°C.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPP
Description: One unit of frozen CPP contains approximately 3.4 x 10\^11 irradiated platelets and approximately 6% DMSO in sterile 0.9% sodium chloride solution (total volume of 20 mL to 35 mL) stored frozen at ≤ -65°C.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPP
Description: One unit of frozen CPP contains approximately 3.4 x 10\^11 irradiated platelets and approximately 6% DMSO in sterile 0.9% sodium chloride solution (total volume of 20 mL to 35 mL) stored frozen at ≤ -65°C.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LSP

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LSP

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LSP

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LSP
Study: NCT02932280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Neratinib will be administered orally, or through existing gastrostomy feeding tube, once a day with food, preferably in the morning, continuously for 28-day cycles, with no rest between cycles. Dose will be scaled by body surface area (BSA).
Study: NCT02854436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Participants will receive 300 mg niraparib (3 capsules\*100 mg) orally once daily.
Study: NCT00627627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-504
Description: dose of 400 mg/m2 as a 30-60 minute IV infusion as part of a 21-day treatment cycle
Study: NCT03355859

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JWCAR029
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with JWCAR029 by intravenous (IV) injection.
Study: NCT03985033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: leucocyte and platelet-rich fibrin (L-PRF)
Description: The blood collected from each patient will be centrifuged immediately at 2700 rpm for 12 min to separate L-PRF.
Study: NCT04998253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Effects in oxygenation and hypoxic pulmonary vasoconstriction
Description: Determination of the anti-inflammatory effect. The anti-inflammatory effect is assessed with serum measurement of interleukin 6 (IL-6), C-reactive protein (CRP), ferritin, DHL (lactic dehydrogenase), taken by venipuncture on admission, at 24 and 48 hours.~The following measurements will be performed: pulmonary artery systolic and diastolic pressure (PASP, PADP respectively), central venous pressure (CVP), pulmonary artery occlusion pressure (PAOP), pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), right ventricular stroke work (RVSW) and left ventricular work (LVSW). Stroke volume (and cardiac output) will be computed using the thermodilution technique averaging three consecutive injections with 10 ml of 0.9% saline solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effects in oxygenation and hypoxic pulmonary vasoconstriction
Description: Determination of the anti-inflammatory effect. The anti-inflammatory effect is assessed with serum measurement of interleukin 6 (IL-6), C-reactive protein (CRP), ferritin, DHL (lactic dehydrogenase), taken by venipuncture on admission, at 24 and 48 hours.~The following measurements will be performed: pulmonary artery systolic and diastolic pressure (PASP, PADP respectively), central venous pressure (CVP), pulmonary artery occlusion pressure (PAOP), pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), right ventricular stroke work (RVSW) and left ventricular work (LVSW). Stroke volume (and cardiac output) will be computed using the thermodilution technique averaging three consecutive injections with 10 ml of 0.9% saline solution.
Study: NCT01901146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 980
Description: ABP 980 was administered at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab was administered at an initial dose of 8 mg/kg over a 90-minute IV infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel, 175 mg/m² Q3W for 4 cycles (or 80 mg/m² QW for 12 cycles, if local standard of care).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel, 175 mg/m² Q3W for 4 cycles (or 80 mg/m² QW for 12 cycles, if local standard of care).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection
Study: NCT01497873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: 1.5 mg/m\^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belotecan
Description: 0.5 mg/m\^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more
Study: NCT03241849

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Modified surgical technique for placenta accreta
Description: suturing of the myometrium splitted by the placenta in cases presented by placenta accreta
Study: NCT02044302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Study: NCT02917837

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual QCNL DI utilization report
Description: See arm descriptions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual QCNL DI utilization report
Description: See arm descriptions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New DI utilization report
Description: See arm descriptions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New DI utilization report
Description: See arm descriptions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detailing
Description: In-person detailing, usually with a small group of family physicians and a peer (physician) facilitator to discuss the topic over a 30-60 minute period.
Study: NCT04240821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline ER
Description: Oral theophylline
Study: NCT01304836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advagraf
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: oral
Study: NCT02917837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Detailing
Description: In-person detailing, usually with a small group of family physicians and a peer (physician) facilitator to discuss the topic over a 30-60 minute period.
Study: NCT02328001

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Debriefing endoscopists of the procedure accessory costs
Description: Informing endoscopists of the number of accessories used and the dollar value of the accessories
Study: NCT00087399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antidepressant
Study: NCT00913471

Intervention type: OTHER
Intervention: blood samples
Description: Chronic patients - a one time blood sample (12 mL) and questionnaire; 10 subjects will donate a 3-5mm skin tissue sample.~Longitudinal Patients - 5 blood samples (12 mL each, totaling 60 mL at the following time points: within 48 hours, one week, one month, 6 months and 18 months post injury to coincide with standard visits) and questionnaire. 10 subjects will donate a 3-5mm skin sample.~Healthy, pain free volunteers - a one time blood sample (12 mL), vital signs per standard CRU protocol and questionnaire confirming they are healthy.

Intervention type: OTHER
Intervention: blood samples
Description: Chronic patients - a one time blood sample (12 mL) and questionnaire; 10 subjects will donate a 3-5mm skin tissue sample.~Longitudinal Patients - 5 blood samples (12 mL each, totaling 60 mL at the following time points: within 48 hours, one week, one month, 6 months and 18 months post injury to coincide with standard visits) and questionnaire. 10 subjects will donate a 3-5mm skin sample.~Healthy, pain free volunteers - a one time blood sample (12 mL), vital signs per standard CRU protocol and questionnaire confirming they are healthy.

Intervention type: OTHER
Intervention: blood samples
Description: Chronic patients - a one time blood sample (12 mL) and questionnaire; 10 subjects will donate a 3-5mm skin tissue sample.~Longitudinal Patients - 5 blood samples (12 mL each, totaling 60 mL at the following time points: within 48 hours, one week, one month, 6 months and 18 months post injury to coincide with standard visits) and questionnaire. 10 subjects will donate a 3-5mm skin sample.~Healthy, pain free volunteers - a one time blood sample (12 mL), vital signs per standard CRU protocol and questionnaire confirming they are healthy.
Study: NCT00581386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LTS-D
Description: supra-glottic airway device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProSeal Laryngeal Mask Airway
Description: pre-existing double-lumen supra-glottic device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Tracheal Combitube (ETC)
Description: disposable double-lumen tube
Study: NCT02773888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HS-1000
Study: NCT02762968

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules similar to the experimental treatments.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB
Description: Capsules containing calcium HMB.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB
Description: Capsules containing calcium HMB.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BC30
Description: Bacillus Coagulans GBI-30, 6086 (BC30) mixed in water.
Study: NCT01883999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE® EXCLUDER® Iliac Branch Endoprosthesis
Study: NCT03522090

Intervention type: DIAGNOSTIC_TEST
Intervention: lower neck CT
Description: Computerised tomography of the lower neck done as part of initial CT thorax and lower abdomen
Study: NCT01304836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simulect
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simulect
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: IV \& oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: IV \& oral
Study: NCT02961972

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: monohydrate and micronized creatine
Description: oral supplementation with creatine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral supplementation with maltodextrin (control group)
Study: NCT01568047

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 - 5 mg single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 - 15 mg single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 - 30 mg single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/Carbidopa
Description: Levodopa 100 mg Carbidopa 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/Carbidopa
Description: Levodopa 100 mg Carbidopa 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/Carbidopa
Description: Levodopa 100 mg Carbidopa 25 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levodopa/Carbidopa
Description: Levodopa 100 mg Carbidopa 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/Benzerazide
Description: Levodopa 100 mg Benzerazide 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/Benzerazide
Description: Levodopa 100 mg Benzerazide 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/Benzerazide
Description: Levodopa 100 mg Benzerazide 25 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levodopa/Benzerazide
Description: Levodopa 100 mg Benzerazide 25 mg
Study: NCT00874029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Halt Procedure
Description: The Halt 2000 Electrosurgical Radiofrequency Ablation System is indicated for use in percutaneous, laparoscopic and intraoperative, coagulation and ablation of soft tissue.
Study: NCT05698420

Intervention type: DEVICE
Intervention: Dialysis using the Theranova-400 device.
Description: Patients receive hemodialysis treatment using the Theranova-400 dialyzer.

Intervention type: DEVICE
Intervention: Dialysis using the FX80 device.
Description: Patients receive hemodialysis treatment using the FX80 dialyzer.
Study: NCT02595528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 ophthalmic solution
Description: 1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 ophthalmic solution
Description: 1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 ophthalmic solution
Description: 1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 ophthalmic solution
Description: 1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190584 ophthalmic solution
Description: 1 drop AGN-190584 ophthalmic solution doses A, B and C in the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190584 ophthalmic solution
Description: 1 drop AGN-190584 ophthalmic solution doses A, B and C in the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190584 ophthalmic solution
Description: 1 drop AGN-190584 ophthalmic solution doses A, B and C in the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190584 ophthalmic solution
Description: 1 drop AGN-190584 ophthalmic solution doses A, B and C in the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190584 vehicle
Description: Vehicle to AGN-190584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190584 vehicle
Description: Vehicle to AGN-190584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190584 vehicle
Description: Vehicle to AGN-190584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190584 vehicle
Description: Vehicle to AGN-190584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 + AGN-190584 Combination
Description: 1 drop AGN-199201 and AGN-190584 fixed combination ophthalmic solution in the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 + AGN-190584 Combination
Description: 1 drop AGN-199201 and AGN-190584 fixed combination ophthalmic solution in the eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 + AGN-190584 Combination
Description: 1 drop AGN-199201 and AGN-190584 fixed combination ophthalmic solution in the eye.